ArticleFood science & nutrition2026
The Effects of Flaxseed Consumption on Frailty and Sarcopenia in Patients With Liver Cirrhosis: An Open-Labeled Randomized Controlled Clinical Trial.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effects of Flaxseed Consumption on Frailty and Sarcopenia in Patients With Liver Cirrhosis: An Open-Labeled Randomized Controlled Clinical Trial.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty and sarcopenia are common among patients with liver cirrhosis (LC), which can lead to a higher risk of several morbidities and mortality. The primary goal of this study was to explore the impact of flaxseed consumption on body composition, frailty and sarcopenia, as well as disease severity and inflammation in these patients. In this 12-week, open-labeled randomized clinical trial, we recruited fifty patients with LC who were randomly allocated to receive either flaxseed (30 g/d flaxseed powder) or no intervention. Body composition and anthropometric parameters, high-sensitive C-reactive protein (hs-CRP), the model for end-stage liver disease-Na (MELD-Na), frailty, sarcopenia, and muscle strength were assessed at the initiation and upon completion of the trial. After the study was completed, percent of body fat (PBF) and waist circumference (WC) decreased significantly in the flaxseed group when compared to the group's pre-intervention values (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.